Autoimmune disease: A role for new anti-viral therapies?

Autoimmunity Reviews

Volumn 11, Issue 2, 2011, Pages 88-97

  Dreyfus, David H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic autoimmune urticaria; Epstein Barr Virus Infection; HERV; HIV 1; Immunopathology; Multiple sclerosis; Rheumatoid Arthritis; RNAi; RNAse P EGS; Systemic Lupus Erythematosus; Vaccines; XLP

Indexed keywords

ACICLOVIR; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; OMALIZUMAB; RALTEGRAVIR; RITUXIMAB; VIRUS VACCINE; 2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; B LYMPHOCYTE; CHRONIC AUTOIMMUNE URTICARIA; CHRONIC IDIOPATHIC URTICARIA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; EPIGENETICS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EVIDENCE BASED MEDICINE; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; MEDLINE; MEMORY CELL; MULTIPLE SCLEROSIS; REMISSION; RETROVIRUS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VIRUS PATHOGENESIS; VIRUS REPLICATION; CHRONIC DISEASE; DRUG EFFECT; ENDOGENOUS RETROVIRUS; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; URTICARIA; VACCINATION; VIROLOGY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIVIRAL AGENTS; AUTOIMMUNITY; B-LYMPHOCYTES; CHRONIC DISEASE; ENDOGENOUS RETROVIRUSES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; INTEGRASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPROLIFERATIVE DISORDERS; MULTIPLE SCLEROSIS; PYRROLIDINONES; RNA, SMALL INTERFERING; URTICARIA; VACCINATION; VIRAL VACCINES;

EID: 84858233979     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.08.005     Document Type: Review

References (116)

1. Kaplan A.P., Joseph K., Maykut R.J., Geba G.P., Zeldin R.K. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008, 122:569-573.
2. Maurer M., Weller K., Bindslev-Jensen C., Gimenez-Arnau A., Bousquet P.J., Bousquet J., et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011, 66:317-330.
3. Dreyfus D.H., Fraser B., Randolph C.C. The syndrome of thyroid autoimmunity and idiopathic chronic urticaria and angioedema presenting as anaphylaxis. Allergy Asthma Proc 2003, 24:171-174.
4. Dreyfus D.H. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. Ann Allergy Asthma Immunol 2008, 100:624-625.
5. Kaplan A.P., Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009, 39:777-787.
6. Agmon-Levin N., Lian Z., Shoenfeld Y. Explosion of autoimmune diseases and the mosaic of old and novel factors. Cell Mol Immunol 2011, 8:189-192.
7. Barzilai O., Sherer Y., Ram M., Izhaky D., Anaya J.M., Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007, 1108:567-577.
8. Mathias S.D., Dreskin S.C., Kaplan A., Saini S.S., Spector S., Rosen K.E. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2010, 105:142-148.
9. Saini S., Rosen K.E., Hsieh H.J., Wong D.A., Conner E., Kaplan A., et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H(1)-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011, (Epub ahead of print).
10. Balfour H.H., Hokanson K.M., Schacherer R.M., Fietzer C.M., Schmeling D.O., Holman C.J., et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol 2007, 39:16-21.
11. Friedman J.E., Zabriskie J.B., Plank C., Ablashi D., Whitman J., Shahan B., et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005, 11:286-295.
12. Meng Q., Hagemeier S.R., Fingeroth J.D., Gershburg E., Pagano J.S., Kenney S.C. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol 2010, 84:4534-4542.
13. Sawada S., Takei M., Inomata H., Nozaki T., Shiraiwa H. What is after cytokine-blocking therapy, a novel therapeutic target-synovial Epstein-Barr virus for rheumatoid arthritis. Autoimmun Rev 2007, 6:126-130.
14. Dreyfus D.H. The DDE recombinases: diverse roles in acquired and innate immunity. Ann Allergy Asthma Immunol 2006, 97:567-576. quiz 76-8, 602.
15. Dreyfus D.H. Paleo-immunology: evidence consistent with insertion of a primordial herpes virus-like element in the origins of acquired immunity. PLoS One 2009, 4:e5778.
16. Nadal M., Mas P.J., Blanco A.G., Arnan C., Sola M., Hart D.J., et al. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc Natl Acad Sci USA 2010, 107:16078-16083.
17. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359:355-365.
18. Hare S., Vos A.M., Clayton R.F., Thuring J.W., Cummings M.D., Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010, 107:20057-20062.
19. Liao C., Marchand C., Burke T.R., Pommier Y., Nicklaus M.C. Authentic HIV-1 integrase inhibitors. Future Med Chem 2010, 2:1107-1122.
20. Beck-Engeser G.B., Eilat D., Harrer T., Jack H.M., Wabl M. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc Natl Acad Sci USA 2009, 106:20865-20870.
21. Brudek T., Christensen T., Aagaard L., Petersen T., Hansen H.J., Moller-Larsen A. B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity. Retrovirology 2009, 6:104.
22. Hsiao F.C., Tai A.K., Deglon A., Sutkowski N., Longnecker R., Huber B.T. EBV LMP-2A employs a novel mechanism to transactivate the HERV-K18 superantigen through its ITAM. Virology 2009, 385:261-266.
23. Petersen T., Moller-Larsen A., Thiel S., Brudek T., Hansen T.K., Christensen T. Effects of interferon-beta therapy on innate and adaptive immune responses to the human endogenous retroviruses HERV-H and HERV-W, cytokine production, and the lectin complement activation pathway in multiple sclerosis. J Neuroimmunol 2009, 215:108-116.
24. Sutkowski N., Chen G., Calderon G., Huber B.T. Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen. J Virol 2004, 78:7852-7860.
25. Sutkowski N., Conrad B., Thorley-Lawson D.A., Huber B.T. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001, 15:579-589.
26. Sutkowski N., Palkama T., Ciurli C., Sekaly R.P., Thorley-Lawson D.A., Huber B.T. An Epstein-Barr virus-associated superantigen. J Exp Med 1996, 184:971-980.
27. Tai A.K., Lin M., Chang F., Chen G., Hsiao F., Sutkowski N., et al. Murine Vbeta3+ and Vbeta7+ T cell subsets are specific targets for the HERV-K18 Env superantigen. J Immunol 2006, 177:3178-3184.
28. Epstein M.A. Historical background. Philos Trans R Soc Lond B Biol Sci 2001, 356:413-420.
29. Bach J.F. Six questions about the hygiene hypothesis. Cell Immunol 2005, 233:158-161.
30. Okada H., Kuhn C., Feillet H., Bach J.F. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010, 160:1-9.
31. Thorley-Lawson D.A. EBV the prototypical human tumor virus-just how bad is it?. J Allergy Clin Immunol 2005, 116:251-261. quiz 62.
32. Thorley-Lawson D.A., Duca K.A., Shapiro M. Epstein-Barr virus: a paradigm for persistent infection-for real and in virtual reality. Trends Immunol 2008, 29:195-201.
33. Hadinoto V., Shapiro M., Greenough T.C., Sullivan J.L., Luzuriaga K., Thorley-Lawson D.A. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 2008, 111:1420-1427.
34. Hadinoto V., Shapiro M., Sun C.C., Thorley-Lawson D.A. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009, 5:e1000496.
35. Roughan J.E., Thorley-Lawson D.A. The intersection of Epstein-Barr virus with the germinal center. J Virol 2009, 83:3968-3976.
36. Dreyfus D.H., Kelleher C.A., Jones J.F., Gelfand E.W. Epstein-Barr virus infection of T cells: implications for altered T-lymphocyte activation, repertoire development and autoimmunity. Immunol Rev 1996, 152:89-110.
37. Dreyfus D.H. Role of T cells in EBV-infected systemic lupus erythematosus patients. J Immunol 2005, 175:3460. author reply 1.
38. Dreyfus D.H. Immunopathology associated with Epstein-Barr Virus (EBV) infection: evidence for interactions with T-lymphocyte EBV receptor CD21. Clin Appl Immunol Rev 2005, 5:241-256.
39. Epstein M.A. Reflections on Epstein-Barr virus: some recently resolved old uncertainties. J Infect 2001, 43:111-115.
40. Thorley-Lawson D.A., Allday M.J. The curious case of the tumour virus: 50years of Burkitt's lymphoma. Nat Rev Microbiol 2008, 6:913-924.
41. Bassiri H., Janice Yeo W.C., Rothman J., Koretzky G.A., Nichols K.E. X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. Immunol Res 2008, 42:145-159.
42. Nichols K.E., Hom J., Gong S.Y., Ganguly A., Ma C.S., Cannons J.L., et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005, 11:340-345.
43. Pachlopnik Schmid J., Canioni D., Moshous D., Touzot F., Mahlaoui N., Hauck F., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117:1522-1529.
44. Tosato G., Steinberg A.D., Blaese R.M. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med 1981, 305:1238-1243.
45. Tosato G., Steinberg A.D., Yarchoan R., Heilman C.A., Pike S.E., De Seau V., et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest 1984, 73:1789-1795.
46. Takei M., Mitamura K., Fujiwara S., Horie T., Ryu J., Osaka S., et al. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. Int Immunol 1997, 9:739-743.
47. Gaston J.S., Rickinson A.B., Epstein M.A. Epstein-Barr virus-specific cytotoxic T cell responses in rheumatoid arthritis patients. Rheumatol Int 1982, 2:155-159.
48. Balandraud N., Meynard J.B., Auger I., Sovran H., Mugnier B., Reviron D., et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 2003, 48:1223-1228.
49. Balandraud N., Roudier J., Roudier C. Epstein-Barr virus and rheumatoid arthritis. Autoimmun Rev 2004, 3:362-367.
50. Sawada S., Takei M. Epstein-Barr virus etiology in rheumatoid synovitis. Autoimmun Rev 2005, 4:106-110.
51. Lee Y.H., Bae S.C., Song G.G. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2010, (Epub ahead of print).
52. Harley J.B., James J.A. Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis 2006, 64:45-50.
53. James J.A., Harley J.B., Scofield R.H. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006, 18:462-467.
54. James J.A., Kaufman K.M., Farris A.D., Taylor-Albert E., Lehman T.J., Harley J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997, 100:3019-3026.
55. James J.A., Neas B.R., Moser K.L., Hall T., Bruner G.R., Sestak A.L., et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44:1122-1126.
56. Kang I., Quan T., Nolasco H., Park S.H., Hong M.S., Crouch J., et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004, 172:1287-1294.
57. Poole B.D., Scofield R.H., Harley J.B., James J.A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006, 39:63-70.
58. Poole B.D., Templeton A.K., Guthridge J.M., Brown E.J., Harley J.B., James J.A. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev 2009, 8:337-342.
59. Quan T.E., Roman R.M., Rudenga B.J., Holers V.M., Craft J.E. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2010, 62:1693-1701.
60. McClain M.T., Poole B.D., Bruner B.F., Kaufman K.M., Harley J.B., James J.A. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 2006, 54:360-368.
61. Gross A.J., Hochberg D., Rand W.M., Thorley-Lawson D.A. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005, 174:6599-6607.
62. Murray E., Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010, 29:707-716.
63. Ascherio A., Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000, 11:220-224.
64. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286:3083-3088.
65. Lunemann A., Tackenberg B., DeAngelis T., da Silva R.B., Messmer B., Vanoaica L.D., et al. Impaired IFN-gamma production and proliferation of NK cells in multiple sclerosis. Int Immunol 2011, 23:139-148.
66. Lunemann J.D., Edwards N., Muraro P.A., Hayashi S., Cohen J.I., Munz C., et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006, 129:1493-1506.
67. Lunemann J.D., Huppke P., Roberts S., Bruck W., Gartner J., Munz C. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008, 71:1033-1035.
68. Lunemann J.D., Jelcic I., Roberts S., Lutterotti A., Tackenberg B., Martin R., et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 2008, 205:1763-1773.
69. Lunemann J.D., Munz C. EBV in MS: guilty by association?. Trends Immunol 2009, 30:243-248.
70. Lunemann J.D., Tintore M., Messmer B., Strowig T., Rovira A., Perkal H., et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010, 67:159-169.
71. Pender M.P. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev 2009, 8:563-568.
72. Pender M.P. The essential role of epstein-barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011, 17:351-367.
73. Pender M.P., Csurhes P.A., Lenarczyk A., Pfluger C.M., Burrows S.R. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:498-505.
74. Pender M.P., Csurhes P.A., Pfluger C.M., Burrows S.R. Decreased CD8+ T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurol 2011, 11:95.
75. Pender M.P., Csurhes P.A., Pfluger C.M., Burrows S.R. CD8 T cell deficiency impairs control of Epstein-Barr virus and worsens with age in multiple sclerosis. J Neurol Neurosurg Psychiatry 2011, (Epub ahead of print).
76. Kakalacheva K., Munz C., Lunemann J.D. Viral triggers of multiple sclerosis. Biochim Biophys Acta 2011, 1812:132-140.
77. Munger K., Levin L., O'Reilly E., Falk K., Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011, (Epub ahead of print).
78. Aloisi F., Serafini B., Magliozzi R., Howell O.W., Reynolds R. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 2010, 133:e157.
79. Serafini B., Severa M., Columba-Cabezas S., Rosicarelli B., Veroni C., Chiappetta G., et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 2010, 69:677-693.
80. Bourdette D., Yadav V. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep 2008, 8:417-418.
81. Chaudhuri A., Behan P.O. Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:2646. author reply-7.
82. Dalakas M.C. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008, 4:557-567.
83. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
84. Leussink V.I., Lehmann H.C., Meyer zu Horste G., Hartung H.P., Stuve O., Kieseier B.C. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity. J Neurol 2008, 255:1436-1438.
85. Petereit H.F., Moeller-Hartmann W., Reske D., Rubbert A. Rituximab in a patient with multiple sclerosis-effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008, 117:399-403.
86. Reske D., Haupt W.F. Use of rituximab in multiple sclerosis: current progress and future perspectives. Expert Rev Clin Immunol 2008, 4:573-582.
87. Schrijver H.M. Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:2645. author reply 6-7.
88. Grossman C., Dovrish Z., Shoenfeld Y., Amital H. Do infections facilitate the emergence of systemic sclerosis?. Autoimmun Rev 2011, 10:244-247.
89. Baudino L., Yoshinobu K., Dunand-Sauthier I., Evans L.H., Izui S. TLR-mediated up-regulation of serum retroviral gp70 is controlled by the Sgp loci of lupus-prone mice. J Autoimmun 2010, 35:153-159.
90. Baudino L., Yoshinobu K., Morito N., Santiago-Raber M.L., Izui S. Role of endogenous retroviruses in murine SLE. Autoimmun Rev 2010, 10:27-34.
91. Vezina H.E., Balfour H.H., Weller D.R., Anderson B.J., Brundage R.C. Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. J Clin Pharmacol 2010, 50:734-742.
92. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266:1981-1986.
93. Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R., Davies D.R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci USA 1998, 95:9150-9154.
94. Michelini Z., Galluzzo C.M., Negri D.R., Leone P., Amici R., Bona R., et al. Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. J Virol Methods 2010, 168:272-276.
95. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354.
96. Yilmaz A., Gisslen M., Spudich S., Lee E., Jayewardene A., Aweeka F., et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009, 4:e6877.
97. Epstein M.A., Morgan A.J., Finerty S., Randle B.J., Kirkwood J.K. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985, 318:287-289.
98. Epstein M.A., Randle B.J., Finerty S., Kirkwood J.K. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin Exp Immunol 1986, 63:485-490.
99. Morgan A.J., Allison A.C., Finerty S., Scullion F.T., Byars N.E., Epstein M.A. Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. J Med Virol 1989, 29:74-78.
100. North J.R., Morgan A.J., Thompson J.L., Epstein M.A. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci USA 1982, 79:7504-7508.
101. Arnson Y., Shoenfeld Y., Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009, 42:553-560.
102. Kaveri S.V., Maddur M.S., Hegde P., Lacroix-Desmazes S., Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011, 164(Suppl 2):2-5.
103. Maddur M.S., Kaveri S.V., Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 2011, (Epub ahead of print).
104. Krause I., Blank M., Shoenfeld Y. Peptide immunotherapy in autoimmune diseases. Drug News Perspect 2000, 13:78-84.
105. Krause I., Blank M., Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Crit Rev Immunol 2000, 20:1-16.
106. Shoenfeld Y., Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
107. Stephenson M.L., Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978, 75:285-288.
108. Zamecnik P.C., Goodchild J., Taguchi Y., Sarin P.S. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci USA 1986, 83:4143-4146.
109. Dreyfus D.H., Tompkins S.M., Fuleihan R., Ghoda L.Y. Gene silencing in the therapy of influenza and other respiratory diseases: targeting to RNase P by use of External Guide Sequences (EGS). Biologics 2007, 1:425-432.
110. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A., Hopmans E.S., Lindenberg J.L., et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010, 107:6328-6333.
111. Dreyfus D.H. Immune system: success owed to a virus?. Science 2009, 325:392-393.
112. Dreyfus D.H. Oncogenesis in ataxia telangectasia: roles of ATM, p53, Nf-kappa-B and DDE recombination pathogenesis. Molecular Mechanisms of Ataxia Telangectasia 2009.
113. Unanue E.R. Viral infections and nonspecific protection-good or bad?. N Engl J Med 2007, 357:1345-1346.
114. Girschick H.J., Guilherme L., Inman R.D., Latsch K., Rihl M., Sherer Y., et al. Bacterial triggers and autoimmune rheumatic diseases. Clin Exp Rheumatol 2008, 26:S12-S17.
115. Abu-Shakra M., Buskila D., Ehrenfeld M., Conrad K., Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001, 60:433-441.
116. Szekanecz Z., Szekanecz E., Bako G., Shoenfeld Y. Malignancies in autoimmune rheumatic diseases-a mini-review. Gerontology 2011, 57:3-10.